Kingfisher Capital LLC Sells 1,623 Shares of Agilent Technologies, Inc. (NYSE:A)

Kingfisher Capital LLC lessened its holdings in Agilent Technologies, Inc. (NYSE:A) by 6.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 22,751 shares of the medical research company’s stock after selling 1,623 shares during the period. Kingfisher Capital LLC’s holdings in Agilent Technologies were worth $3,378,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of A. Massachusetts Financial Services Co. MA boosted its position in Agilent Technologies by 3.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company’s stock valued at $2,314,784,000 after purchasing an additional 525,214 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Agilent Technologies by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock valued at $442,011,000 after buying an additional 183,716 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Agilent Technologies by 4.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,948,536 shares of the medical research company’s stock valued at $437,799,000 after buying an additional 136,184 shares in the last quarter. Impax Asset Management Group plc grew its position in shares of Agilent Technologies by 8.2% in the 3rd quarter. Impax Asset Management Group plc now owns 2,667,616 shares of the medical research company’s stock worth $396,088,000 after buying an additional 203,234 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in Agilent Technologies by 2.3% during the second quarter. Victory Capital Management Inc. now owns 2,386,039 shares of the medical research company’s stock valued at $309,302,000 after acquiring an additional 52,550 shares during the last quarter. 87.42% of the stock is currently owned by institutional investors.

Agilent Technologies Trading Up 2.8 %

Shares of Agilent Technologies stock opened at $138.14 on Friday. Agilent Technologies, Inc. has a fifty-two week low of $124.10 and a fifty-two week high of $155.35. The stock has a 50 day moving average of $137.65 and a 200 day moving average of $137.44. The firm has a market capitalization of $39.69 billion, a price-to-earnings ratio of 28.66, a PEG ratio of 5.91 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78.

Agilent Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st will be issued a $0.248 dividend. This represents a $0.99 annualized dividend and a yield of 0.72%. The ex-dividend date is Tuesday, December 31st. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.24. Agilent Technologies’s dividend payout ratio (DPR) is 20.54%.

Analyst Ratings Changes

Several research analysts recently weighed in on A shares. Evercore ISI boosted their target price on Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. TD Cowen upped their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. StockNews.com cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday. JPMorgan Chase & Co. cut their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $143.40.

Insiders Place Their Bets

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. This represents a 19.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.33% of the stock is owned by insiders.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.